LSTA — LISATA THERAPEUTICS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 320017 ·
Last close
$1.76
Market Cap
$15.86M
52W High
$4.04
52W Low
$0.99
ADV30
376,050
Next earnings
2026-11-05
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. Lisata Therapeutics, Inc. was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. in September 2022. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. As of July 21, 2026, Lisata Therapeutics, Inc. operates as a subsidiary of Kuva Labs, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 0 -3,992,000 -2,929,000 11,027,000 10,443,000 3,037,000
Mar 2026 0 -4,942,000 -4,489,000 14,059,000 13,060,000 3,387,000
Dec 2025 100,000 -3,079,000 -2,954,000 17,744,000 15,956,000 3,143,000
Sep 2025 0 -4,414,000 -4,249,000 21,759,000 18,998,000 4,640,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-12,323,000
Investing CF
$5,150,000
Financing CF
$768,000
CapEx
$-28,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.85
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-572,070,000
Inventory
Receivables
$0
ST Investments
$0
EBIT TTM
$-16,427,000
Pretax Income TTM
$-15,008,000
Interest Exp TTM
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$100,000
EBITDA
$-16,362,000
Free Cash Flow
$-8,100,250
Enterprise Value
$5,162,249
Total Cash
$10,443,000
Total Debt
$0
Shares Out
9,010,937
Trailing EPS
$-1.64
Book Value
$0.90
ROE
-101.7%
ROA
-56.7%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 170,000 -18,209,000 -16,586,000 17,744,000 3,143,000 -15,949,000
Dec 2024 1,000,000 -22,409,000 -19,985,000 35,002,000 5,685,000 -19,356,000
Dec 2023 0 -25,708,000 -20,840,000 54,694,000 6,800,000 -20,032,000
Dec 2022 0 -57,601,000 -54,225,000 73,034,000 6,710,000 -21,170,000
Dec 2021

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-6,927,000
OpCashFlow TTM
$0
Assets (Latest)
$35,002,000
Forward EPS
$-1.16

Peers — same industry

TickerNameMarket CapLastDaily %
CMMB Chemomab Therapeutics Ltd. $15.90M $2.17
CTXR Citius Pharmaceuticals, Inc. $15.80M $0.58
HIND Vyome Holdings, Inc $15.74M $2.24
OTLC Oncotelic Therapeutics, Inc. $16.01M $0.04
PBM PSYENCE BIOMEDICAL LTD. $16.10M $4.22

News headlines (Yahoo Finance, 1h cache)

Lisata Therapeutics moves forward with legal action following Kuva merger termination
2026-08-04 12:48 · Yahoo
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
2026-08-04 11:00 · Yahoo
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
2026-06-10 13:36 · Yahoo
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
2026-06-10 12:00 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-07-24 19:35 · Yahoo
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
2026-03-09 14:29 · Yahoo
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
2026-03-06 23:15 · Yahoo
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
2026-01-27 13:00 · Yahoo
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
2026-01-22 12:04 · Yahoo
How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook
2026-01-22 07:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.